So proud of our amazing PGY5 Kathryn Ries Tringale helping to reinvigorate and modernize the use of #radiation for #pcnsl at #ASH22 Joachim (Achy) Yahalom Memorial Sloan Kettering Radiation Oncology MSKHemOncTrials

🚨New JAMA Network Open PGY5 Dr Emily Lebow, MD: Tumor mutational burden-high status was associated with ⬆️ local-regional control & PFS after definitive chemorads/adjuvant durvalumab. TMB status may facilitate risk-adaptive #radiation strategies for #lcsm. jamanetwork.com/journals/jaman…

Tumor mutational burden may be a novel biomarker to facilitate personalized radiotherapy for locally advanced lung cancer. ja.ma/3X9h3Ri Emily Lebow, MD Memorial Sloan Kettering Radiation Oncology

Study by Emily Lebow, MD, Narek Shaverdian & colleagues find high TMB status was associated with improved PFS after definitive chemoradiation & adjuvant durvalumab in those with unresectable locally advanced #NSCLC 🫁 #OpenAccess study in JAMA Network Open ➡️ bit.ly/3ZgroN3

New from former Memorial Sloan Kettering Cancer Center #proton Dr Anna Lee with Nancy Lee: Compared with previous reports of photon-based #reirradiation, pts are living longer with aggressive proton-ReRT; however, surviving pts remain at risk of early & late complications. jamanetwork.com/journals/jaman…

It's a Match! Welcome to Memorial Sloan Kettering Cancer Center #radonc!! 🥳 🙌Kathryn Hockemeyer MD, PhD 🙌Gideon Haber, MD 🙌Elisa Liu, MD 🙌Revathi Ravella, MD 🙌Alexander Terry, MD 🙌Shoshana Rosenzweig, MD We're excited to have you join us in New York! #Match2023 #radoncMatch2023

🚨A #radonc away rotation Memorial Sloan Kettering Cancer Center means a month to explore the best of NYC: our cancer center, outstanding faculty, & what residency in the city that never sleeps really feels like🚕🌃🥯☕️ For July-December: Apply🔜via VSLO For June: 📩 [email protected] #match2024

☢️🫁 New in @RadiotherapyOn1 from Dr Emily Lebow, MD: We observed excellent long-term disease control with #SBRT for #sarcoma pulmonary metastases & potential for prolonged survival particularly among pts with oligometastatic disease at the time of SBRT. sciencedirect.com/science/articl…

🎙 SBRT for #sarcoma 🫁metastases achieved high rates of local control w/ low toxicity❗️🚨OncoAlert @RadiotherapyOn1 📌retro single 🏥study 🥇🎯: Local failure 📊RESULTs 👉66 👥w/ 95 🫁metastases 👉local failure at 12 & 24 m 3.1% &7.4% 👉OS at 12 & 24 m 74% & 49%

In Frontiers we highlight the potential of #ctDNA to guide personalized therapy for patients with #lungcancer Thank you Natera Oncology, @Natera, Yonina Murciano-Goroff , Bob Li, Daniel Gomez, Andreas Rimner & many more at Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center! 🔗 tinyurl.com/3pcmj6rd

In this study, giving an antibody-drug conjugates (T-DXd, T-DM1, SG) concurrently with stereotactic radiotherapy was associated w/ higher risk of radiation necrosis. The absolute risk was low for small lesions, but increased rapidly w/ volume & prior RT. ja.ma/498qFCq

Happy to share our work on SRS with concurrent ADCs, now out JAMA Oncology! In this study, led by Emily Lebow, MD, we investigated the risk of symptomatic radiation necrosis for pts receiving SRS and brain metastases. ADCs included T-DXd, T-DM1, and SG. (1/n) jamanetwork.com/journals/jamao…

Just out in JAMA Oncology - important data on risk factors for #brainmet necrosis with concurrent ADC + SRS: understanding sequencing essential as CNS outcome data emerge Memorial Sloan Kettering Radiation Oncology MSK Department of Medicine Neurosurgery at Memorial Sloan Kettering Emily Lebow, MD Yao Yu @Dr_Luke_Pike Nelson Moss

🫁☢️New in Journal for ImmunoTherapy of Cancer from Memorial Sloan Kettering Cancer Center #radonc and Dana-Farber: This analysis of outcomes to #chemoradiation & #durvalumab in stage III non-small cell #lungcancer #NSCLC suggests that tumor aneuploidy is a promising predictive biomarker. #lcsm ➡️jitc.bmj.com/content/11/11/…

🧠☢️⚡️New in JAMA Oncology from Memorial Sloan Kettering Cancer Center #radonc grad Dr Emily Lebow, MD w/ Dr Yao Yu: Antibody-drug conjugates given concurrently with Stereotactic #radiotherapy #SRS were associated with ⬆️risk of symptomatic #radiation necrosis. More details here: jamanetwork.com/journals/jamao…

Thanks, Henning Willers, MD, FASTRO! Great to present promising options for pts with locally advanced #lungcancer who are ineligible for chemoRT. Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology

#CARTcells for #DIPG #DMG clinical trial (1st arm) results are out today. Full Tweetorial coming, but first want to share the story of a patient whose #DIPG has disappeared for over 3 years. It is a milestone and moment of hope on a journey filled with so much grief. “There’s a

The National Comprehensive Cancer Network (NCCN) Foundation has announced MCC member, Kathryn Tringale, MD, MAS, as a 2025 Young Investigator Award recipient. This award recognizes her impact on cancer care through neuroimaging and biomarker research on neurotoxicity after CAR T-cell therapy: bit.ly/4iQpoo1.

#ASCO25: Stephen Bagley on CAR T cell for glioblastoma: “The treatment changed the trajectory of their disease.” Now in Nature Medicine and on the ASCO stage today. Abstract 102. DrORourke spr.ly/6018N7k16

Congratulations to Iris Gibbs, MD, FASTRO; Helen Shih, MD, MS, MPH, FASTRO; & Joachim Yahalom, MD, FASTRO on their 2025 ASTRO Mentorship awards!! They will be recognized at #ASTRO25 in San Francisco. Stanford Radiation Oncology MassGeneral News Memorial Sloan Kettering Radiation Oncology ow.ly/A1cB50WlXIa